Chronic controlled stimulant prescribing documentation guidelines
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Governs documentation and monitoring requirements for practitioners who prescribe controlled stimulant medications for more than 90 days to members of BlueCross BlueShield of Tennessee.
No material clinical or coverage changes in this revision.
Coverage Criteria
Advance writing of stimulant prescriptions for durations longer than 90 days without an evaluation of the member at the time the prescription is written is considered inappropriate. This policy explicitly states that advance writing of stimulant prescriptions for greater than 90 days without member evaluation at the time of the prescription is inappropriate and should not be done.
Key Timelines & Definitions
Provider Actions & Requirements
Prior Authorization Required
Prior Authorization Required. Prior authorization is required for chronic (greater than 90 days) prescriptions of controlled stimulant medications when applicable under the member's benefit plan. Obtain approval before dispensing extended-duration prescriptions or any refill authorizations that would result in >90 days supply without an in-person evaluation.
- Applies to any controlled stimulant prescribed for >90 days without documented member evaluation at time of prescription
- Document prior authorization number in the medical record and on the claim when required
Step Therapy May Apply
Step Therapy: Step therapy requirements may apply. When plan benefits include step therapy for stimulant therapies, prescribers must document trial and failure or contraindication of required first-line agents per the member's benefit design before coverage of non-preferred stimulants will be approved.
- Document prior trials (drug name, dose, duration, and reason for failure or intolerance)
- If a required step is bypassed, include clinical rationale and supporting documentation in the record for review
Required documentation for chronic stimulant prescribing
When a controlled substance is prescribed chronically (>90 days), the practitioner should keep accurate and complete records which should include documentation and/or evidence of the following: 1. Individualized specific findings and course of treatment 2. Legible entries that are not cloned and do not use copy and paste of similar or identical statements from visit to visit or member to member 3. Completion of a mental and physical examination that screens for and diagnoses any comorbidities prior to prescribing 4. Update of mental and physical examination at least yearly 5. Details of relevant member behavior supporting the stimulant prescribing; and, for minors, the same information gathered from the member's responsible party and also teachers where applicable 6. FDA approved diagnosis that is consistent with the prescription written 7. If prescribed for ADD/ADHD, symptomatic behavior present before the age of 12 8. Complete medication list with consideration of concurrently prescribed controlled substances or other medications that may reduce the desired effects 9. Treatment planning and effectiveness, side effects, and changes made in the prescribing treatment 10. Education of risks, appropriate use, administration, and storage of medication, or this same education provided to the responsible party of a minor member 11. In the event of suspected misuse or diversion of the prescribed stimulant, pill count, drug testing, discussion of aberrant results, and/or completion of a risk assessment for treatment referral of a substance use disorder 12. Controlled Substance Monitoring Database has been checked at the initial prescription and at least every six months with written evidence either of no discrepancies or a discussion of all discrepancies with the member or responsible party 13. Advance writing of stimulant prescriptions for greater than 90 days without member evaluation at the time of the prescription is inappropriate Network practitioners who prescribe controlled stimulants and do not comply with these guidelines are subject to disciplinary action by BCBST that may include credentials revocation, network contract terminations, and a report filed with the National Practitioner Data Bank (NPDB) or other entities mandated by law.
Noncompliance Consequences
Noncompliance consequences. Failure to follow the documentation, monitoring, prior authorization, or step therapy requirements may result in disciplinary actions including credentialing impacts, contract termination, referral to regulatory bodies, and potential denial of payment.
- May include credentials revocation, network contract termination, and reporting to NPDB or other mandated entities
- Claims lacking required prior authorization or without clinical justification for step therapy override are subject to denial
Background
This policy defines minimum clinical documentation and monitoring expectations for practitioners who prescribe controlled stimulant medications chronically (defined as >90 days). Practitioners must keep accurate, complete records including individualized findings and course of treatment; legible, non-cloned notes; baseline mental and physical examination that screens for comorbidities; and updates of the mental and physical exam at least yearly.
Documentation must also include details of relevant member behavior supporting the stimulant prescribing (and for minors, information gathered from the responsible party and teachers as applicable), an FDA-consistent diagnosis, and when treating ADD/ADHD, evidence that symptomatic behavior was present before age 12.
Clinical records should contain a complete medication list (including concurrent controlled substances), treatment planning with monitoring of effectiveness and side effects, and documentation of patient or responsible-party education about risks, appropriate use, administration, and storage. If misuse or diversion is suspected, providers should document actions taken such as pill counts, drug testing, discussion of aberrant results, and/or completion of a risk assessment for referral.
Practitioners must check the Controlled Substance Monitoring Database (PDMP) at the initial prescription and at least every six months, with written evidence of either no discrepancies or documentation of discussion of any discrepancies with the member or responsible party. Failure to comply with these documentation and monitoring expectations may subject network practitioners to disciplinary action, including credential revocation, network contract termination, and reporting to the NPDB or other mandated entities.
Definitions
Stimulant Prescribing Criteria
Stimulant prescribing — documentation and monitoring criteria
Covered when ALL of the following documentation and monitoring requirements are met for chronic stimulant prescriptions (>90 days):
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.